IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure

August 17, 2026 8:30 AM

IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage biotechnology company developing therapeutics and AI-enabled tools for Alzheimer's disease, today announced financial results for the second quarter ended June 30, 2026, and provided an update on the Company's lead Alzheimer's program, IGC-AD1. During the second quarter, the Phase 2 CALMA trial of IGC-AD1 reached the Company's previously disclosed 146-patient baseline randomization...

Read more

NatureCell to Open the Era of "Medicine for Humanity (蒼生醫學)" with the World's First Commercialization of Amniotic Stem Cell Conditioned Medium

August 17, 2026 8:00 AM

NatureCell announced its vision to usher in an era of "Medicine for Humanity (蒼生醫學)" by commercializing amniotic stem cell conditioned medium (CM) for the first time in the world and making advanced stem cell technologies more economical and convenient for people around the world.The latest research supporting this vision was published in the international scientific journal Cells on August 13, 2026.The study investigated the use of amniotic...

Read more

CARR Biosystems Acquires Alfa Wassermann, Expanding Its Bioprocessing Portfolio

August 14, 2026 9:00 AM

CARR Biosystems, a provider of separation and bioprocessing technologies for the pharmaceutical and biotechnology industries, today announced it has acquired Alfa Wassermann (AW), a leader in continuous flow ultracentrifugation and fluid handling solutions, from Turytes S.p.A.. The transaction closed on August 10th.For more than 60 years, AW has designed, manufactured and serviced continuous flow ultracentrifugation systems used to separate,...

Read more

Notice Of Annual General Meeting in Biovica International AB

August 14, 2026 2:20 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - The shareholders of Biovica International AB, reg. no. 556774-6150 (the "Company"), are hereby invited to the annual general meeting to be held on Wednesday 16 September 2026, at 15.00 CEST at Conference Hubben, Dag Hammarskjölds Väg 38 in Uppsala.Right to attend the general meetingShareholders wishing to attend the annual general meeting must:i. on the record date, which is on...

Read more

Lifeloc Reports Second Quarter 2026 Results

August 13, 2026 4:18 PM

Lifeloc Technologies, Inc. (OTCID:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quarter ended June 30, 2026.Second Quarter Financial HighlightsLifeloc posted quarterly net revenue of $2.445 million in the second quarter of 2026, resulting in a quarterly net loss of $(134) thousand, or $(0.05) per diluted share. These results compare to net revenue...

Read more

First Ascent Biomedical Names Dr. Gilberto Lopes Chairman of Its Medical Advisory Board

August 13, 2026 2:25 PM

First Ascent Biomedical, a precision oncology company developing biology-driven cancer treatment decision support, today announced the appointment of Gilberto Lopes, M.D., as Chairman of the company's Medical Advisory Board.Dr. Lopes is Professor of Clinical Medicine and Chief of the Division of Medical Oncology at the University of Miami Miller School of Medicine. He also serves as Associate Director for Global Oncology at Sylvester...

Read more

AlivaMab Biologics and Ablexis Congratulate Boulevard Bio on its Launch and the Ongoing Phase 1 Clinical Trial of Bispecific Antibody BLVD101

August 13, 2026 9:30 AM

AlivaMab Biologics, LLC ("AMB"), a leader in the discovery and engineering of superior biologic drugs, and Ablexis, LLC ("Ablexis"), a biopharmaceutical company advancing human antibody drug discovery through the provision of its AlivaMab® Mouse technology, congratulate Boulevard Bio on its launch and the ongoing Phase 1 clinical trial for BLVD101, a dual neutralizing bispecific antibody for the treatment of autoimmune diseases."Working in close...

Read more

Microbix Reports Results for Q3 Fiscal 2026

August 13, 2026 7:50 AM

Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its third quarter and nine months of fiscal 2026 ended June 30, 2026 ("Q3" and "YTD"). Results for Q3 and YTD continue to demonstrate the results of the Company's continuing work to rebuild revenues back to profitability following two client setbacks in mid-2025, with revenue growth of 17% in Q3 compared to Q3...

Read more

Lobe Sciences Ltd. Announces Non-Brokered Private Placement

August 12, 2026 8:45 AM

Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FSE:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, is pleased to announce a non-brokered private placement offering of 24,705,880 common shares in the capital of the Company ("Common Shares") at a price of $0.085 per Common Share, for aggregate gross proceeds of approximately $2,100,000 (the "Private...

Read more

Levita Magnetics Brings MARS(R) Magnetic Surgery Platform to Florida for the First Time

August 12, 2026 6:00 AM

Levita Magnetics, a Silicon Valley medical technology company advancing minimally invasive surgery, has performed its first Magnetic Surgery procedures in Florida using the MARS® platform. The milestone marks the Florida debut of MARS® at HCA Florida Mercy Hospital in Miami, the first hospital in the state to offer this technology, expanding access to less invasive surgery in Florida.Built on Levita's proprietary Dynamic Magnetic Positioning™...

Read more

Invitation to FluoGuide A/S Live Webcast on 25 August 2026

August 12, 2026 5:08 AM

FluoGuide A/S (STO:FLUO) will publish its interim report for Q2 2026 on Tuesday, 25 August 2026.Later that day, CEO Morten Albrechtsen and CFO Ole Larsen will present the company's operational and financial results for Q2 2026 in a live webcast. The webcast is hosted and moderated by Cecilia Hallström, BioStock.The presentation will be followed by a live Q&A session, where questions can be asked during the event or submitted in advance by e-mail...

Read more

eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026

August 11, 2026 4:10 PM

CEO of eXoZymes, Michael Heltzen, will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer period.Investors can pre-register for the webinar HERE.On the day of the event, the live webinar can also be accessed through eXoZymes' investor relations website at https://exozymes.com/investor.About eXoZymesFounded in...

Read more

OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development

August 11, 2026 8:52 AM

OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from its Chief Executive Officer to shareholders.Dear Shareholders,Today marks five business days before August 18, the practical deadline by which the Nasdaq is expected to communicate its determination regarding OSRH's continued listing if our stock price has not regained the minimum bid price requirement of $1.00 per share as of the market close.As CEO of OSRH, I want to...

Read more

IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout

August 11, 2026 8:30 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing treatments for Alzheimer's disease, today announced that it is strengthening its regulatory, biostatistical, artificial intelligence ("AI")-enabled data science, and strategic pharmaceutical development capabilities as IGC-AD1, the Company's lead Alzheimer's drug candidate, advances toward expected Phase 2 topline results in the...

Read more

Remedium Bio Announces Initial Close of Series A Financing to Advance Durable Protein Therapeutics Platform Toward First-in-human Clinical Development

August 10, 2026 9:00 AM

Remedium Bio, Inc. ("Remedium"), a biotechnology company developing durable protein therapeutics, today announced the initial closing of its planned $10 million Series A financing. The round is led by Lifespan Vision Ventures, with participation from Eli Lilly and Company ("Lilly") and HKX Capital. In connection with the financing, Harry Robb of Lifespan Vision Ventures has joined Remedium's Board of Directors.Remedium's proprietary platforms...

Read more

OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program

August 7, 2026 3:00 PM

OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today issued a clarification regarding its press release dated July 31, 2026 concerning the Nasdaq Stock Market ("Nasdaq") and the Company's Shareholder Loyalty CVR Program.The Company is clarifying that the statement in the prior release, "The communication affirms that our loyalty program is additive and gives shareholders clarity," should not be interpreted as indicating that...

Read more

Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform

August 7, 2026 8:35 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported financial results for the quarter ended June 30, 2026, and provided a corporate update on continued execution of its long-term strategy to advance its proprietary DNase platform through scientific collaboration and translational...

Read more

BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Ovarian Cancer

August 7, 2026 5:20 AM

BioInvent International AB ("BioInvent") (NASDAQ Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BI-1808, a first-in-class anti-TNFR2 antibody, for the treatment of ovarian cancer in combination with pembrolizumab."Receiving FDA Fast Track Designation for BI-1808 in ovarian cancer is an important milestone that...

Read more

Biomind Labs Announces Listing on the Canadian Securities Exchange and the Delisting From the Cboe Canada

August 6, 2026 4:15 PM

Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND)(OTC PINK:BMNDF), a clinical-stage biopharmaceutical company focused on transforming breakthroughs in neuroscience and biomedical research into novel pharmaceutical drugs, is pleased to announce that it has received approval to list its common shares (the "Common Shares") on the Canadian Securities Exchange (the "CSE"), and the Common Shares will commence trading on the CSE at market open...

Read more

Microbix Schedules Release of Results for Q3 Fiscal 2026

August 6, 2026 7:00 AM

Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF), (Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its third quarter of fiscal 2026 ended June 30, 2026 ("Q3 2026") prior to the start of trading on August 13, 2026. At 10:00 AM ET that day, Microbix intends to hold a webinar discussion of Q3 2026 results...

Read more